This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/resource/domain/vavai/subjekt/
n8http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n19http://bibframe.org/vocab/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F11%3A00002542%21RIV12-MZ0-00023001/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F11%3A00002542%21RIV12-MZ0-00023001
rdf:type
n8:Vysledek skos:Concept
rdfs:seeAlso
http://www.springerlink.com/content/g143h770r414l23v/
dcterms:description
Introduction. Response rates and overall outcome for patients who have failed first-line and in some cases second-line chemotherapy are as low as 12% and 7 months, respectively. The aim of this study is to evaluate the efficacy of hepatic arterial sulfonate hydrogel microsphere (drug-eluting beads), irinotecan preloaded therapy (DEBIRI) in metastatic colorectal cancer refractory to systemic chemotherapy. Methods. This was a multicenter multinational single-arm study of metastatic colorectal cancer patients who received DEBIRI after failing systemic chemotherapy from 10/2006 to 8/2008. Primary endpoints were safety, tolerance, tumor response rates, and overall survival. Results. Fifty-five patients who had received prior systemic chemotherapy and who underwent a total of 99 DEBIRI treatments were reviewed. The median number of DEBIRI treatments was 2 (range 1-5), median treatment dose was 100 mg (range 100-200 mg), with total hepatic treatment of 200 mg (range 200-650 mg), with 86% of treatments performed as lobar infusion and 30% of patients treated with concurrent simultaneous chemotherapy. Adverse events occurred in 28% of patients with median grade of 2 (range 1-3) with no deaths at 30 days post procedure. Response rates were 66% at 6 months and 75% at 12 months. Overall survival in these patients was 19 months, with progression-free survival of 11 months. Conclusions. Hepatic arterial drug-eluting bead, irinotecan (DEBIRI) was safe and effective in treatment of metastatic colorectal cancer (MCC) refractory to multiple lines of systemic chemotherapy. DEBIRI is an acceptable therapy for treatment of metastatic colorectal cancer to the liver. Introduction. Response rates and overall outcome for patients who have failed first-line and in some cases second-line chemotherapy are as low as 12% and 7 months, respectively. The aim of this study is to evaluate the efficacy of hepatic arterial sulfonate hydrogel microsphere (drug-eluting beads), irinotecan preloaded therapy (DEBIRI) in metastatic colorectal cancer refractory to systemic chemotherapy. Methods. This was a multicenter multinational single-arm study of metastatic colorectal cancer patients who received DEBIRI after failing systemic chemotherapy from 10/2006 to 8/2008. Primary endpoints were safety, tolerance, tumor response rates, and overall survival. Results. Fifty-five patients who had received prior systemic chemotherapy and who underwent a total of 99 DEBIRI treatments were reviewed. The median number of DEBIRI treatments was 2 (range 1-5), median treatment dose was 100 mg (range 100-200 mg), with total hepatic treatment of 200 mg (range 200-650 mg), with 86% of treatments performed as lobar infusion and 30% of patients treated with concurrent simultaneous chemotherapy. Adverse events occurred in 28% of patients with median grade of 2 (range 1-3) with no deaths at 30 days post procedure. Response rates were 66% at 6 months and 75% at 12 months. Overall survival in these patients was 19 months, with progression-free survival of 11 months. Conclusions. Hepatic arterial drug-eluting bead, irinotecan (DEBIRI) was safe and effective in treatment of metastatic colorectal cancer (MCC) refractory to multiple lines of systemic chemotherapy. DEBIRI is an acceptable therapy for treatment of metastatic colorectal cancer to the liver.
dcterms:title
Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study
skos:prefLabel
Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study
skos:notation
RIV/00023001:_____/11:00002542!RIV12-MZ0-00023001
n8:predkladatel
n12:ico%3A00023001
n4:aktivita
n6:I n6:N
n4:aktivity
I, N
n4:cisloPeriodika
1
n4:dodaniDat
n5:2012
n4:domaciTvurceVysledku
n17:7562829
n4:druhVysledku
n16:J
n4:duvernostUdaju
n9:S
n4:entitaPredkladatele
n13:predkladatel
n4:idSjednocenehoVysledku
201896
n4:idVysledku
RIV/00023001:_____/11:00002542
n4:jazykVysledku
n14:eng
n4:klicovaSlova
phase-II trial; arterial infusion; randomized trial; folinic acid; oxaliplatin; fluorouracil; leucovorin; cancer
n4:klicoveSlovo
n7:arterial%20infusion n7:folinic%20acid n7:leucovorin n7:cancer n7:oxaliplatin n7:phase-II%20trial n7:fluorouracil n7:randomized%20trial
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[54EC06B7688A]
n4:nazevZdroje
Annals of surgical oncology
n4:obor
n11:FD
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
10
n4:rokUplatneniVysledku
n5:2011
n4:svazekPeriodika
18
n4:tvurceVysledku
Bosnjakovik, Petar Joshi, Jonathan Tomalty, Dana Martin, Robert C.g Derner, Milous Robbins, Ken Tatum, Cliff Scupchenko, Alexander Padr, Radek Roček, Miloslav
n4:wos
000286486700032
s:issn
1068-9265
s:numberOfPages
7
n19:doi
10.1245/s10434-010-1288-5